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Introduction
Patients with advanced cancer receiving chemotherapy generally require multiple medications for concurrent illnesses, treatment-related toxicities or for pain control. There is growing interest in potential anti-tumour properties of some prescription drugs; conversely, there is that these same drugs may increase the likelihood of adverse drug interactions. The most recent analysis of concomitant medications taken by cancer patients suggests that patients take an average of 4.8 prescription drugs, 1.6 non-prescription drugs and 1.6 other remedies within the 3 days before chemotherapy. 1 The large database (n = 1006) of the TAX 327 study provided us with an opportunity to evaluate concomitant medications taken by the patients at baseline and their influence on treatment outcomes. TAX 327 was a landmark study showing survival advantage in men treated with docetaxel 3 times weekly compared to docetaxel once a week and mitoxantrone as initial chemotherapy for castrate-resistant, metastatic prostate cancer. 2 
Methods
We identified patients taking selected concomitant medications while receiving study treatment as part of the TAX 327 study. We examined 14 types of medications (metformin, digoxin, verapamil, proton pump inhibitors, nitrates, statins, cox-2 inhibitors, warfarin, heparins, ascorbic acid, selenium, tocopherol, antidepressants and erythropoietin) taken concurrently with chemotherapy and prednisone and analyzed them for their association with overall survival (primary endpoint), PSA-response rate, percent PSA-reduction from baseline to on-treatment nadir, pain-response and quality of life (QOL)-response. Each of these measures was defined as per the TAX 327 study, 2 aside from PSA shrinkage (Appendix 1). Each of these selected medications was taken by at least 20 men in the study. Medications were selected because of their putative anti-neoplastic effects (Table 1) . We detailed selected data suggesting that specific concurrent medications have an effect on outcome measures in Table 2 and Table 3 (greater details in Appendix 2 to 9). For all outcomes, both unadjusted tests and adjusted tests were examined. Unless otherwise specified, the adjusted test results are discussed in the text with both sets of results presented in the online supplementary tables. Overall survival was estimated using the Kaplan-Meier method, and is based on the updated survival analysis. 3 Cox proportional hazards models were used to estimate the hazards ratio (HR) and p-value comparing patients who received each concomitant medication to those who did not receive it. The proportion of patients having a PSA-response, differences in PSA reduction, pain-response and QOL-response were calculated for patients receiving (or not) each concomitant medication. The unadjusted p-value was calculated using Fisher's exact test, and adjusted p-values using the Cochran-Mantel-Haenszel test, adjusted for treatment group. The homogeneity of odds ratios was tested using the Breslow-Day test and used to determine whether the estimated odds ratio is different between the three treatment groups. Duration of intravenous chemotherapy was compared using Wilcoxon rank sum tests (unadjusted analysis) and linear regression (adjusted analysis). The median and inter-quartile range was calculated for patients receiving (or not) each concomitant medication, and these were compared using the Wilcoxon rank sum test. Statistical significance was set at p = 0.05 and no p-value adjustment was performed for multiple hypothesis testing. All tests were two-sided. 
Digoxin
Inhibition of HIF1. 4, 5 Digitalis inhibits proliferation of prostate cancer cell lines.
12

Nitrates
Attenuates hypoxia induced tumour growth/drugresistance. 13 Prolonged PSA doubling time with use of glyceryl trinitrate in recurrent prostate cancer patients in a phase II study.
14
PPI
Tumour alkalization, inhibition of autophagy and P-glycoprotein antagonist. 15 Limited evidence.
Verapamil
Reversal of multidrug resistance, inhibition of voltagegated K+ channel. 16, 17 However, CYP3A4 inhibitor, potentially increasing docetaxel concentration. 18 Inhibition of proliferation in LNCaP. 6 
Statins
Inhibitory effects on angiogenesis, cell proliferation and invasion. 19 However, may possibly compete for CYP3A4 metabolism (atorvastatin, lovastatin, simvastatin).
Reduced risk of prostate cancer and of biochemical recurrence after prostatectomy.
20,21
Cox-2 inhibitors
Converts arachnoidic acid to prostaglandins which inhibit apoptosis, stimulate cell proliferation and facilitate angiogenesis.
22
Decreased tumour cell proliferation, microvessel density, angiogenesis and HIF-1 and increased apoptosis associated with celecoxib.
23
Warfarin
Inhibition of fibrin formation, reduction of urokinase receptor expression, and inhibition of thrombin generation, release of metalloproteinase-2 from subendothelial matrix. 24 Also may compete for CYP3A4 with docetaxel for metabolism.
Warfarin showed anti-metastatic activity in pre-clinical prostate cancer models 25 and showed antitumour activity in prostate cancer in a population based study.
8,26
Ascorbic acid
Ascorbic acid: direct cytotoxicity by hydrogenperoxide 27 and antioxidant properties.
Limited evidence.
Lycopene
Lycopene thought to act through Ras and mevalonate. 28 A prospective study of tomato products (lycopene) was associated with decreased prostate cancer risk.
30
Tocopherol
Induces apoptosis via caspase dependent and independent mechanisms in vitro and in vitro. 29 Possibly by affecting interrupting sphingolipid synthesis. 31 May also affect NF-Kb activation. 32 Effects found in prostate cancer cell lines and xenografts. 34 
Selenium
May contribute to elevation of the endogenous inhibitor of angiogenesis, platelet factor-4; 41 inhibiting nuclear translocation of the NF-Kb and the subsequent production of the immunosuppressive cytokine TGFbeta, VEGF and IL-6; 42 increases the activity of PTEN. 43 Evidence from mouse and rat prostate models. 33, 44 Early human evidence of a benefit in preventing carcinogenesis not validated.
Heparins
Possible role in decreasing metastases formation via decreasing adhesion. 35 In vitro models and rat prostate models.
36
Antidepressants
Selective serotonin reuptake inhibitors and monoamine oxidase inhibitors may decrease prostate cancer growth.
38
In vitro proliferation experiments.
37
Erythropoietin May promote growth of prostate cancer cells. 39 Experiments in prostate cancer cell lines and indirect evidence from human tumours.
40
PSA: prostate-specific antigen; PPI: proton pump inhibitors; LNCaP: Human prostate adenocarcinoma cell line; NF-Kb: nuclear factor kappaB; TGF-beta: Transforming Growth Factor-beta; VEGF: Vascular endothelial growth factor; IL-6: interleukin-6; PTEN: phosphatase and tensin homologue.
Results
Patients taking verapamil and digoxin had worse overall survival than patients who did not (adjusted analysis using data from all 3 treatment cohorts: digoxin HR 1.43 (1.01-2.03), p = 0.046; verapamil HR 1.51 (1.10-2.08), p = 0.011). These differences in survival were consistent within each of the 3 treatments, but were most pronounced in the docetaxel 3-weekly treatment group. Interestingly, the duration of intravenous chemotherapy comparing the median duration for those on verapamil with the median duration of those not on verapamil approached statistical significance (unadjusted p = 0.080 and adjusted p = 0.070). Those on verapamil appeared to have reduced weeks on chemotherapy compared with those not on verapamil.
No concomitant medication had a statistically significant effect on PSA-response rate, although men taking warfarin had greater PSA reduction than those not taking it (PSA reduction 49.0% [-5.5, 85.3] vs. 69.2% [20.3, 90.8] , unadjusted p = 0.047, adjusted p = 0.035). Men taking antidepressants had lower rates of pain-response than those not taking antidepressants (unadjusted p = 0.045; CochranMantel-Haenszel [CMH] test p = 0.028; homogeneity of odds ratios p = 0.19). The QOL response rates were significantly higher (unadjusted p = 0.032; CMH p = 0.031; homogeneity of odds ratios p = 0.49) among patients who received cox-2 inhibitors than those who did not.
Discussion
Our analysis revealed a number of possible associations between concomitant medications and outcome measures in the TAX-327 trial. The use of digoxin was associated with poorer overall survival within all three treatment groups. Preclinical studies have shown digoxin to be a potential anticancer agent, 6, 7 but its effects here are likely due to the influence of comorbidity from the cardiac condition for which it was prescribed, an effect that would only be partially accounted for by the stratification for the Karnofsky performance status. Patients who took verapamil also had poorer overall survival, although other efficacy outcomes were not substantially different between those who did and did not take verapamil. This result is contrary to previous suggestions that verapamil can inhibit the proliferation of many tumour types, including prostate cancer, 6 and, in higher does, can block the multi-drug resistance drug efflux pump. Patients receiving digoxin or verapamil probably represented a group of people who were more likely to have death related to cardiovascular disease; although, it is possible that competition for CYP3A4 and the inhibitory ability of verapamil on CYP3A4 also lead to more toxicity, abrogating the length of chemotherapy, a hypothesis supported by the trend to a decreased treatment duration in patients on verapamil. Unfortunately, it is not possible to extract causes of mortality from the trial records to clarify this issue.
Our analysis revealed that the degree of PSA reduction in men taking warfarin was higher than in those not taking this medication. Data are sparse on the effects of warfarin in prostate cancer treatment; a Canadian case-control study showed that 4 years of warfarin use was associated with an adjusted incidence rate ratio of 0.80 (95% CI 0.65-0.99) for prostate cancer compared with that in people who never used warfarin; little research has been carried out subsequently. 10 Patients concurrently taking antidepressants had poorer pain-response rates, and trends to poorer survival and PSAresponse rates (p < 0.10). The poorer pain response may be due to anxiety that was associated with conditions for which these medications were prescribed.
Our analysis of proton pump inhibitors and metformin, drugs with pre-clinical evidence to suggest potential antineoplastic activity (Table 1) , also did not reveal any association with outcome measures, although we noted trends for QOL response (unadjusted p = 0.074; CMH p = 0.074; homogeneity of odds ratios 0.31) for metformin.
Despite pre-clinical, clinical and epidemiological observations that some of these medications are likely to exhibit anticancer properties, we were unable to detect sufficient activity to warrant testing with docetaxel in future studies. There are a number of potential reasons for this. It is impor- tant to note that most preclinical (and clinical) data supporting the potential anti-cancer properties of most of the agents included in these studies were based on reports excluding combinations with chemotherapy; the current analysis, however, focused on the possibility of combined effects. Additionally, our analyses was restricted by the limited data on the pharmacokinectic interactions with docetaxel and the medications listed other than theorectical interactions with verapamil, diltaizem (inhibitors of CYP3A4), numerous SSRIs (selective serotonin reuptake inhibitors) (including citalopram, sertraline, which may compete for CYP 3A4) and some statins (atorvastatin, lovastatin and simvastation, which may also compete for CYP3A4).
Finally, there are a number of limitations of secondary analyses, such as multiple hypothesis testing, patient comorbidities, and small numbers of patients taking individual drugs to the extent that we were unable to confidently exclude the effect of any concomitantly taken medication given the confidence intervals surrounding them. Future efforts may concentrate on recent large clinical trials with patients at earlier stages of disease (and with fewer comorbidities), such as those with asymptomatic metastatic castrate refractory disease. These efforts will allow us to examine these issues in combination with either pharmacogenetic or physiological data to refine an hypothesis (e.g., does the presence of the insulin resistance syndrome portend a shorter response to hormonal therapies that can be reversed with metformin?).
Conclusion
Our data are hypothesis-generating and contain a number of important clinical research negative findings, such as the lack of benefit of metformin and the potentially concerning data about verapamil. This data is the only one of its kind available for prostate cancer. Aside from some case-control analyses of breast cancer populations examining the use of SSRIs and tamoxifen, [45] [46] [47] there are no similar analyses in the literature for any malignancy. Therefore, our study provides 
